US Bancorp DE increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.5% during the second quarter, Holdings Channel reports. The institutional investor owned 1,022,039 shares of the biopharmaceutical company’s stock after buying an additional 144,403 shares during the period. US Bancorp DE’s holdings in Gilead Sciences were worth $72,340,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Hall Laurie J Trustee boosted its position in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares during the last quarter. Cable Hill Partners LLC boosted its position in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 541 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its position in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. boosted its position in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares during the last quarter. Finally, Penserra Capital Management LLC boosted its position in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the last quarter. Institutional investors and hedge funds own 74.06% of the company’s stock.

Shares of Gilead Sciences, Inc. (GILD) traded up 0.71% during trading on Wednesday, hitting $73.79. The stock had a trading volume of 5,772,716 shares. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $82.10. The company’s 50 day moving average price is $70.60 and its 200 day moving average price is $68.59. The company has a market capitalization of $96.37 billion, a price-to-earnings ratio of 8.01 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the previous year, the firm posted $3.08 EPS. The business’s revenue for the quarter was down 8.2% compared to the same quarter last year. Analysts predict that Gilead Sciences, Inc. will post $8.76 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.84%. Gilead Sciences’s payout ratio is 22.58%.

ILLEGAL ACTIVITY WARNING: This piece was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/09/gilead-sciences-inc-gild-position-raised-by-us-bancorp-de.html.

A number of research firms have issued reports on GILD. BidaskClub cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday. J P Morgan Chase & Co set a $85.00 target price on Gilead Sciences and gave the company an “overweight” rating in a research note on Thursday, July 27th. Jefferies Group LLC reissued a “hold” rating and issued a $83.00 target price on shares of Gilead Sciences in a research note on Thursday, July 27th. Deutsche Bank AG reissued a “buy” rating and issued a $81.00 target price (up from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Finally, Leerink Swann reissued a “hold” rating and issued a $74.00 target price on shares of Gilead Sciences in a research note on Tuesday, July 25th. Twelve research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $80.31.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $242,749,648.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the sale, the executive vice president now directly owns 102,988 shares in the company, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. Insiders have sold a total of 206,666 shares of company stock worth $15,223,184 in the last three months. Insiders own 1.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.